Theseus Pharmaceuticals, Inc. Common Stock

THRX

Capitalización de mercado USD 181 M

SAN DIEGO--(BUSINESS WIRE)--As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered into a merger agreement (the “Merger Agreement”) with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) (“Theseus”) whereby Purchaser will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 pe.

NEW ORLEANS , Jan. 22, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus Pharmaceuticals, Inc. (NasdaqGS: THRX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Theseus will receive between $3.90 and $4.05 in cash for each share of Theseus that they own. KSF is seeking to determine whether this consideration and the process that le.

Theseus Pharmaceuticals (THRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

MILWAUKEE , Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Theseus (NASDAQ: THRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join the https://www.ademilaw.com/case/theseus-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) to Concentra Biosciences, LLC for between $3.90 and $4.05 in cash is fair to Theseus shareholders. Halper Sadeh encourages Theseus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation con.

CAMBRIDGE, Mass. , Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share (the "Base Price") and (ii) an additional cash amount of not more than $0.15 per share at the closing of the merger (together with the Base Price, the "Cash Amount"), plus one non-tradeable contingent value right ("CVR") representing the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs effected within 180 days of closing of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger, pursuant to a Contingent Value Rights Agreement (the "CVR Agreement").

Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.

CAMBRIDGE, Mass. , Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by Foresite or OrbiMed in a going-private transaction.